| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/03/2005 | DE10335092B3 Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung Benzoylureido substituted-o-benzoylamide, processes for their preparation and their use |
| 02/03/2005 | DE10332473A1 Ambroxol für die Behandlung von Epilepsie Ambroxol for the treatment of epilepsy |
| 02/03/2005 | DE10332472A1 Ambroxol für die Behandlung von Tinnitus Ambroxol for the treatment of tinnitus |
| 02/03/2005 | DE10329874A1 Tajixanthonhydrat und Tajixanthonhydrat-Derivate, Verfahren zu ihrer Isolierung und Herstellung, biologische Aktivitäten und deren Verwendung Tajixanthonhydrat and Tajixanthonhydrat derivatives, processes for their isolation and preparation, biological activities and their use |
| 02/03/2005 | DE10329295A1 Preparation of pyrrolidine-1,2-dicarboxanilide derivatives for use as factor Xa inhibiting antithrombotic agents, comprises reacting pyrrolidine-2-carboxylic acid with phenyl isocyanate then aniline derivative |
| 02/03/2005 | DE10328813A1 Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA-Sequenzen mittels triplexbildender Oligomere A method for the examination of cytosine methylations in DNA sequences by means triplexbildender oligomers |
| 02/03/2005 | DE10057976B4 Verfahren zur Herstellung von Pektinhydrolyseprodukten A process for producing pectin hydrolysis products |
| 02/03/2005 | CA2770493A1 Cyclohexanecarboxylic acid compound |
| 02/03/2005 | CA2744317A1 Substituted tetracycline compounds |
| 02/03/2005 | CA2546481A1 Substituted furochromenes, preparation thereof and their antiinflammatory action |
| 02/03/2005 | CA2536383A1 Nicotinamide compounds useful as pde4 inhibitors |
| 02/03/2005 | CA2536111A1 Oral compositions for treatment of diseases |
| 02/03/2005 | CA2534438A1 High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins |
| 02/03/2005 | CA2534262A1 Nicotinamide derivatives useful as pde4 inhibitors |
| 02/03/2005 | CA2534178A1 Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| 02/03/2005 | CA2533707A1 Treatment of lesions of the soft tissues |
| 02/03/2005 | CA2533681A1 Nicotinamide derivatives useful as pde4 inhibitors |
| 02/03/2005 | CA2533663A1 Nicotinamide derivatives useful as pde4 inhibitors |
| 02/03/2005 | CA2533662A1 Nicotinamide derivatives useful as pde4 inhibitors |
| 02/03/2005 | CA2533649A1 Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
| 02/03/2005 | CA2533626A1 Quinolinone derivatives as inhibitors of c-fms kinase |
| 02/03/2005 | CA2533624A1 Nicotinamide derivatives useful as pde4 inhibitors |
| 02/03/2005 | CA2533603A1 Nicotinamide derivatives useful as pde4 inhibitors |
| 02/03/2005 | CA2533594A1 Compounds for inflammation and immune-related uses |
| 02/03/2005 | CA2533588A1 Immediate-release formulation of acid-labile pharmaceutical compositions |
| 02/03/2005 | CA2533584A1 Substituted furochromene compounds of antiinflammatory action |
| 02/03/2005 | CA2533555A1 Heparin-derived oligosaccharide mixtures, preparation thereof and pharmaceutical compositions containing said mixtures |
| 02/03/2005 | CA2533494A1 Aryl heteroaromatic products, compositions comprising the same and use thereof |
| 02/03/2005 | CA2533421A1 Use of xmp-629 for the treatment of acne |
| 02/03/2005 | CA2533417A1 Design and synthesis of optimized ligands for ppar |
| 02/03/2005 | CA2533402A1 A1 adenosine receptor antagonists |
| 02/03/2005 | CA2533397A1 Substituted pyridin-2-ylamine analogues |
| 02/03/2005 | CA2533392A1 Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use |
| 02/03/2005 | CA2533384A1 Indolopyrrolocarbazole derivative and antitumor agent |
| 02/03/2005 | CA2533375A1 Crystalline 6-n-pyridylmethylaminoindolocarbazole compounds |
| 02/03/2005 | CA2533367A1 Purine nucleoside analogues for treating flaviviridae including hepatitis c |
| 02/03/2005 | CA2533352A1 Bacteriophage-containing therapeutic agents |
| 02/03/2005 | CA2533136A1 Perinatal hypoxic-ischemic brain damage treatment |
| 02/03/2005 | CA2533117A1 Combinations for the treatment of depression |
| 02/03/2005 | CA2533101A1 Dispersible formulation of an anti-inflammatory agent |
| 02/03/2005 | CA2532982A1 Thienopyridine and furopyridine kinase inhibitors |
| 02/03/2005 | CA2532980A1 2-aminopyrimidine and 2-aminopyridine-4-carbamates for use in the treatment of autoimmune diseases |
| 02/03/2005 | CA2532922A1 Composition and method for treating neurological disorders |
| 02/03/2005 | CA2532908A1 3,5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| 02/03/2005 | CA2532865A1 Fluoro substituted omega-carboxyaryl diphenyl urea for the inhibition of kinase signaling |
| 02/03/2005 | CA2532859A1 Use of rotigotine for the treatment of depression |
| 02/03/2005 | CA2532808A1 Piperidine derivatives as melanocortin-4 receptor agonists |
| 02/03/2005 | CA2532807A1 Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome |
| 02/03/2005 | CA2532802A1 Antibiotic compound isolated from streptomyces sp |
| 02/03/2005 | CA2532800A1 Anaplastic lymphoma kinase modulators and methods of use |
| 02/03/2005 | CA2532798A1 Azepine derivatives as pharmaceutical agents |
| 02/03/2005 | CA2532730A1 Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof |
| 02/03/2005 | CA2532626A1 Particles containing an active agent in the form of a co-precipitate |
| 02/03/2005 | CA2532608A1 Orodispersible pharmaceutical composition of an antithrombotic compound |
| 02/03/2005 | CA2532443A1 Tyrosine kinase inhibitors |
| 02/03/2005 | CA2532433A1 Muscarinic acetylcholine receptor antagonists |
| 02/03/2005 | CA2532400A1 Tyrosine kinase inhibitors |
| 02/03/2005 | CA2532397A1 (2s,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-l-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof |
| 02/03/2005 | CA2532379A1 Muscarinic acetylcholine receptor antagonists |
| 02/03/2005 | CA2532375A1 Muscarinic acetylcholine receptor antagonists |
| 02/03/2005 | CA2532310A1 Pharmaceutical compositions having a swellable coating |
| 02/03/2005 | CA2532249A1 Nicotinamide derivatives useful as pde4 inhibitors |
| 02/03/2005 | CA2532231A1 Aminopyrazole compounds and use as chk1 inhibitors |
| 02/03/2005 | CA2532154A1 Quinoline derivates and their use in therapy |
| 02/03/2005 | CA2532102A1 7 and 8 membered heterocyclic cyclopentyl benzylamide modulators of chemokine receptor activity |
| 02/03/2005 | CA2532084A1 Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences |
| 02/03/2005 | CA2532076A1 Sulfonyldihydroimid- azopyridinone compounds as 5-hydroxytryptamine-6 ligands |
| 02/03/2005 | CA2532071A1 Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands |
| 02/03/2005 | CA2532064A1 Hydroxypyridine cgrp receptor antagonists |
| 02/03/2005 | CA2531912A1 Process for producing 1,2,4-triazole compound and intermediate therefor |
| 02/03/2005 | CA2531728A1 Substituted tetracycline compounds |
| 02/03/2005 | CA2531515A1 Aryl-substituted benzo[d]isothiazol-3-ylamine analogues as capsaicin receptor modulators |
| 02/03/2005 | CA2531490A1 Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands |
| 02/03/2005 | CA2531223A1 Compositions containing prodrugs of florfenicol and methods of use |
| 02/03/2005 | CA2530763A1 Methods for delaying or inducing labor |
| 02/03/2005 | CA2530407A1 Penetration enhancer combinations for transdermal delivery |
| 02/03/2005 | CA2530402A1 Delivery system for topical medications |
| 02/03/2005 | CA2530352A1 Quinolone derivative or salt thereof |
| 02/03/2005 | CA2530302A1 Novel aminobenzophenone compounds |
| 02/03/2005 | CA2530281A1 Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders |
| 02/03/2005 | CA2530085A1 Compositions and methods for the production of betaine lipids |
| 02/03/2005 | CA2530047A1 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
| 02/03/2005 | CA2530046A1 7-substituted camptothecin and camptothecin analogs and methods for preparing same |
| 02/03/2005 | CA2529734A1 2-amino-4-hydroxy-5-pyrimidine carboxamide derivatives and related compounds as inhibitors of t cell activation for the treatment of inflammatory diseases |
| 02/03/2005 | CA2529674A1 The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity |
| 02/03/2005 | CA2529238A1 Triazolotriazine compounds and uses thereof |
| 02/03/2005 | CA2529036A1 Indane derivates as muscarinic receptor agonists |
| 02/03/2005 | CA2528586A1 Cyclohexanecarboxylic acid compound |
| 02/03/2005 | CA2528173A1 Cci-779 isomer c |
| 02/03/2005 | CA2528043A1 Marks as modifiers of the pten pathway and methods of use |
| 02/03/2005 | CA2525829A1 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/03/2005 | CA2522338A1 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 02/03/2005 | CA2521020A1 Annatto extract compositions including tocotrienols and tocopherols and methods of use |
| 02/03/2005 | CA2517260A1 Tetracyclic benzamide derivatives and methods of use thereof |
| 02/03/2005 | CA2499307A1 Treatment of heaves using r-(-)albuterol |
| 02/02/2005 | EP1502962A2 Methods for assessing and treating cancer |
| 02/02/2005 | EP1502916A1 Piperidine derivatives having ccr3 antagonism |
| 02/02/2005 | EP1502604A1 Use of nitric oxide mimetics in cancer treatment |
| 02/02/2005 | EP1502601A1 Use of neurotoxin therapy for treatment of urinary retention |
| 02/02/2005 | EP1502595A1 An injection made from ixeris sonchifolia for treatment of cardio-cerebral vascular disease and fundus diseases and method of producing thereof |